139 related articles for article (PubMed ID: 11517330)
1. Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors.
Wilkinson RW; Ross EL; Poulsom R; Ilyas M; Straub J; Snary D; Bodmer WF; Mather SJ
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10256-60. PubMed ID: 11517330
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a transgenic mouse model for anti-human CEA radioimmunotherapeutics.
Wilkinson RW; Ross EL; Ellison D; Zimmermann W; Snary D; Mather SJ
J Nucl Med; 2002 Oct; 43(10):1368-76. PubMed ID: 12368376
[TBL] [Abstract][Full Text] [Related]
3. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.
Greiner JW; Zeytin H; Anver MR; Schlom J
Cancer Res; 2002 Dec; 62(23):6944-51. PubMed ID: 12460911
[TBL] [Abstract][Full Text] [Related]
4. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
Zeytin HE; Patel AC; Rogers CJ; Canter D; Hursting SD; Schlom J; Greiner JW
Cancer Res; 2004 May; 64(10):3668-78. PubMed ID: 15150127
[TBL] [Abstract][Full Text] [Related]
5. A new mouse model for evaluating the immunotherapy of human colorectal cancer.
Hörig H; Wainstein A; Long L; Kahn D; Soni S; Marcus A; Edelmann W; Kucherlapati R; Kaufman HL
Cancer Res; 2001 Dec; 61(23):8520-6. PubMed ID: 11731437
[TBL] [Abstract][Full Text] [Related]
6. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
7. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy.
Clarke P; Mann J; Simpson JF; Rickard-Dickson K; Primus FJ
Cancer Res; 1998 Apr; 58(7):1469-77. PubMed ID: 9537250
[TBL] [Abstract][Full Text] [Related]
8. Induction of mucosal and systemic immune responses against human carcinoembryonic antigen by an oral vaccine.
Huang Y; Fayad R; Smock A; Ullrich AM; Qiao L
Cancer Res; 2005 Aug; 65(15):6990-9. PubMed ID: 16061685
[TBL] [Abstract][Full Text] [Related]
9. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
10. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice.
Schwegler C; Dorn-Beineke A; Nittka S; Stocking C; Neumaier M
Cancer Res; 2005 Mar; 65(5):1925-33. PubMed ID: 15753392
[TBL] [Abstract][Full Text] [Related]
12. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern.
Eades-Perner AM; van der Putten H; Hirth A; Thompson J; Neumaier M; von Kleist S; Zimmermann W
Cancer Res; 1994 Aug; 54(15):4169-76. PubMed ID: 8033149
[TBL] [Abstract][Full Text] [Related]
13. [Expression of tumor-associated antigen LEA and its significance for pathological diagnosis].
Feng H; Song JD
Ai Zheng; 2002 Jun; 21(6):658-62. PubMed ID: 12452070
[TBL] [Abstract][Full Text] [Related]
14. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen.
Bos R; van Duikeren S; Morreau H; Franken K; Schumacher TN; Haanen JB; van der Burg SH; Melief CJ; Offringa R
Cancer Res; 2008 Oct; 68(20):8446-55. PubMed ID: 18922918
[TBL] [Abstract][Full Text] [Related]
15. Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: an animal model for CEA-directed tumor immunotherapy.
Thompson JA; Eades-Perner AM; Ditter M; Muller WJ; Zimmermann W
Int J Cancer; 1997 Jul; 72(1):197-202. PubMed ID: 9212243
[TBL] [Abstract][Full Text] [Related]
16. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
17. Microdistribution of targeted, fluorescently labeled anti-carcinoembryonic antigen antibody in metastatic colorectal cancer: implications for radioimmunotherapy.
Fidarova EF; El-Emir E; Boxer GM; Qureshi U; Dearling JL; Robson MP; Begent RH; Trott KR; Pedley RB
Clin Cancer Res; 2008 May; 14(9):2639-46. PubMed ID: 18451227
[TBL] [Abstract][Full Text] [Related]
18. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
19. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A
Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for recurrent colorectal cancers with human monoclonal antibody SK-1.
Koda K; Glassy MC; McKnight ME; Yasutomi J; Saito N; Dan M; Nakajima N
Anticancer Res; 2001; 21(1B):621-7. PubMed ID: 11299816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
